DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck announced today that ONFI Tablets are now available for prescribing in the United States. The FDA recently approved ONFI for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years and older.1 ONFI is an oral anti-epileptic drug (AED) of the benzodiazepine class, and is a 1,5 benzodiazepine.1 ONFI (pronounced “ON-fe”) is a federally controlled schedule four substance (C-IV).
